<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671122</url>
  </required_header>
  <id_info>
    <org_study_id>AZ, Molndal, Sweden grant 1377</org_study_id>
    <nct_id>NCT03671122</nct_id>
  </id_info>
  <brief_title>PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm Heart Failure Study</brief_title>
  <acronym>PREFERS</acronym>
  <official_title>PREFERS PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm Heart Failure Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) with preserved (HFpEF) or reduced (HFrEF) ejection fraction is associated&#xD;
      with poor prognosis and quality of life. While the incidence of HFrEF is declining and HF&#xD;
      treatment is effective, HFpEF is increasing, with no established therapy. PREFERS Stockholm&#xD;
      is an epidemiological study with the aim of improving clinical care and research in HF and to&#xD;
      find new targets for drug treatment in HFpEF starting with a cardiac biopsy study in elective&#xD;
      CABG patiens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with new-onset HF (n = 2000) will be characterized at baseline and after 1-year&#xD;
      follow-up by standardized protocols for clinical evaluation, echocardiography, and ECG. In&#xD;
      one subset undergoing elective coronary bypass surgery (n = 100) and classified according to&#xD;
      LV function, myocardial biopsies will be collected during surgery, and cardiac magnetic&#xD;
      resonance (CMR) imaging will be performed at baseline and after 1 year. Blood and tissue&#xD;
      samples will be stored in a biobank.We will characterize and compare new-onset HFpEF and&#xD;
      HFrEF patients regarding clinical findings and cardiac imaging, genomics, proteomics, and&#xD;
      transcriptomics from blood and cardiac biopsies, and by established biomarkers of fibrosis,&#xD;
      inflammation, haemodynamics, haemostasis, and thrombosis. The data will be explored by&#xD;
      state-of-the-art bioinformatics methods to investigate gene expression patterns, sequence&#xD;
      variation, DNA methylation, and post-translational modifications, and using systems biology&#xD;
      approaches including pathway and network analysis.In this epidemiological HF study with&#xD;
      biopsy studies in a subset of patients, we aim to identify new biomarkers of disease&#xD;
      progression and to find pathophysiological mechanisms to support explorations of new&#xD;
      treatment regimens for HFpEF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fibrotic biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>For the biopsies (CABG PREFERS), the sample size is based upon the number of patients undergoing elective CABG surgery. Investigators expect to discover mRNAs from genes of potential interest in this material with relevance to differences between preserved ejection fraction, reduced ejection fraction and normal groups by bioinformatics tools. These genes will be further investigated in the blood samples of the PREFERS study and potentially in future heart biopsies. for the PREFERS new onset heart failure study. Investigators calculated a 20% difference between HFrEF and HFpEF groups with regard to both PICP and CITP (higher PICP levels and lower CITP in HFpEF vs. HFrEF) as clinically meaningful. To detect a 20% difference between the HFpEF and the HFrEF groups with 80% power and with an estimated drop-out rate of 50 patients in each group, 250 patients in each group are needed to obtain samples from 200 per group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reverse remodeling</measure>
    <time_frame>2 years</time_frame>
    <description>diastolic function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac magnetic resonance tomography imaging</measure>
    <time_frame>2 years</time_frame>
    <description>ECV by cMRI will be correlated to type of HF whether HFpEF or HFrEF and to echocardiographic findings</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">683</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Heart Failure，Congestive</condition>
  <arm_group>
    <arm_group_label>PREFERS main study</arm_group_label>
    <description>500 patients with new onset heart failure will be characterized into those with HFpEFand HFrEF at baseline and undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG PREFERS</arm_group_label>
    <description>500 Patients undergoing elective by pass surgery with or without diastolic or systolic dysfunction as Proxy for HFpEF and HFrEF will undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis and cardiac biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac imaging in the PREFERS and CABG PREFERS cohorts</intervention_name>
    <description>performed at baseline and after 1 year</description>
    <arm_group_label>CABG PREFERS</arm_group_label>
    <arm_group_label>PREFERS main study</arm_group_label>
    <other_name>Doppler echocardiography and cMRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker analysis in the PREFERS and CABG PREFERS chorts</intervention_name>
    <description>blood samples will be taken for biomarker analysis at baseline and after 1 year</description>
    <arm_group_label>CABG PREFERS</arm_group_label>
    <arm_group_label>PREFERS main study</arm_group_label>
    <other_name>blood samples</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac biopsies in the CABG PREFERS cohort</intervention_name>
    <description>myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG</description>
    <arm_group_label>CABG PREFERS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      In 500 of the included 1000 patients (CABG-PREFERS) needle biopsies are taken from the&#xD;
      cardiac lateral wall of both the right and left ventricle before initiation of cardiac arrest&#xD;
      and stored in -70 ∘C for histological and genetic analysis. Moreover biopsies are taken from&#xD;
      the right atrial appendage (ample material), the right and left ventricular myocardium, as&#xD;
      wellas from the internal mammary artery.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CABG PREFERS: Patients undergoing elective coronary artery by pass surgery at the&#xD;
        karolinska University hospital PREFERS: New onset heart failure patients at 5 hospitals in&#xD;
        Stockholm ; Danderyds Hospital, Capio St Görans Hospital , Karolinska Solna Karolinska&#xD;
        Huddinge, South Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:CABG PREFERS&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Patients undergoing elective coronary bypass surgery&#xD;
&#xD;
          2. History of heart failure not required&#xD;
&#xD;
          3. Age &gt;18 years&#xD;
&#xD;
          4. Willingness to participate (written informed consent)&#xD;
&#xD;
          5. Possibility to obtain technically satisfactory echocardiography&#xD;
&#xD;
        Inclusion criteria PREFERS:&#xD;
&#xD;
          1. New-onset heart failure according to ESC guidelines including NT-proBNP &gt;125 ng/L at&#xD;
             heart failure clinic or &gt;300 ng/L at emergency department visit or hospital admission&#xD;
&#xD;
          2. Age &gt;18 years&#xD;
&#xD;
          3. Willingness to participate (written informed consent)&#xD;
&#xD;
          4. Possibility to obtain technically satisfactory echocardiography&#xD;
&#xD;
        Exclusion Criteria CABG PREFERS and PREFERS:&#xD;
&#xD;
          1. Cognitive impairment&#xD;
&#xD;
          2. Inability to understand Swedish language&#xD;
&#xD;
          3. Anaemia (haemoglobin level &lt;90 g/L)&#xD;
&#xD;
          4. Heart failure primarily due to valvular disease, primary right ventricular failure,&#xD;
             pulmonary artery hypertension, hypertrophic obstructive cardiomyopathy Infiltrative&#xD;
             cardiomyopathy (e.g. amyloidosis, sarcoidosis, or haemochromatosis)&#xD;
&#xD;
          5. Severe co-morbidity, severe COPD, severe renal dysfunction (eGFR &lt;30 mL/min/1.73m2).&#xD;
             Any other co-morbid disease that will disable the ability to assess or treat heart&#xD;
             failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecilia M Linde, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institution of Internal medicine, Karolinska University Hospital and Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Linde C, Eriksson MJ, Hage C, Wallén H, Persson B, Corbascio M, Lundeberg J, Maret E, Ugander M, Persson H; Stockholm County/Karolinska Institutet 4D heart failure investigators. Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants. Eur J Heart Fail. 2016 Oct;18(10):1287-1297. doi: 10.1002/ejhf.599. Epub 2016 Jul 7.</citation>
    <PMID>27384611</PMID>
  </results_reference>
  <results_reference>
    <citation>Asp M, Salmén F, Ståhl PL, Vickovic S, Felldin U, Löfling M, Fernandez Navarro J, Maaskola J, Eriksson MJ, Persson B, Corbascio M, Persson H, Linde C, Lundeberg J. Spatial detection of fetal marker genes expressed at low level in adult human heart tissue. Sci Rep. 2017 Oct 11;7(1):12941. doi: 10.1038/s41598-017-13462-5.</citation>
    <PMID>29021611</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 9, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Cecilia Linde</investigator_full_name>
    <investigator_title>MD PhD Senior Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>none described</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

